Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Joji Mori"'
Autor:
Yu Nakamura, Yukimichi Imai, Masahiro Shigeta, Ana Graf, Toru Shirahase, Hyosung Kim, Akifumi Fujii, Joji Mori, Akira Homma
Publikováno v:
Dementia and Geriatric Cognitive Disorders Extra, Vol 1, Iss 1, Pp 163-179 (2011)
Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s disease (AD) in 64 countries. Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and tol
Externí odkaz:
https://doaj.org/article/752c75f6bfca4637bfe80e509795d760
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Makoto, Nishio, Yuichiro, Ohe, Kadoaki, Ohashi, Ryo, Toyozawa, Miyako, Satouchi, Nobuyuki, Sekine, Joji, Mori, Sotaro, Enatsu, Koichi, Goto
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 49(6)
Selpercatinib is a highly selective, potent, rearranged during transfection(RET)inhibitor. A global, multicenter, open-label, phase 1/2 study of selpercatinib(LIBRETTO-001, NCT03157128)has been ongoing since 2017. We evaluated the data of Japanese pa
Autor:
Yoichi Naito, Masaomi Tajimi, Koichi Inoue, Karim A. Benhadji, Hiroya Asou, Joji Mori, Toshihiko Doi
Publikováno v:
Investigational New Drugs
SummaryBackground This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid tum
Autor:
Seiichiro, Mitani, Yucherng, Chen, Koichi, Inoue, Joji, Mori, Ling, Gao, Amanda, Long, Satoshi, Wakabayashi
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 48(11)
We evaluated the safety and potential clinical impact of shortened ramucirumab infusion in Japanese patients from clinical studies.Multivariate logistic regression analysis was used to assess any association between infusion rate and increased risk o
Autor:
Yoshinori Tanizawa, Matthew P. Goetz, Masato Takahashi, Jan-Stefan van der Walt, Masakazu Toi, Eriko Tokunaga, Joji Mori, Tsutomu Kawaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC). Metho
Autor:
Makoto Kodaira, Toshihiro Kudo, Koichi Inoue, Kenji Nakano, Sachi Sakaguchi, Yuichi Ando, Joji Mori, Gerard J. Oakley, Taroh Satoh, Shunji Takahashi, Kenji Tamura, Tomoya Shimokata, Kan Yonemori
Publikováno v:
Cancer Science
Olaratumab, a monoclonal antibody targeting human platelet‐derived growth factor receptor α, plus doxorubicin significantly improved overall survival in patients with advanced soft‐tissue sarcoma (STS) in a prior phase 1b/2 randomized trial. Sub
Autor:
P. Kellie Turner, Edward M. Chan, Yuko Tanabe, Shunsuke Kondo, Noboru Yamamoto, Ken Ogasawara, Yutaka Fujiwara, Kenji Tamura, Hiroya Asou, Satoru Iwasa, Akihiko Shimomura, Joji Mori, Shigehisa Kitano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78:281-288
To confirm the safety and tolerability, evaluate the pharmacokinetics (PK), and investigate the antitumor activity of abemaciclib in Japanese patients with advanced cancer.We conducted a non-randomized, single-arm, open-label, dose-escalation phase 1
Autor:
Joji Mori, Yutaka Kano
Publikováno v:
Pharmaceutical Statistics. 14:464-470
The crossover trial design (AB/BA design) is often used to compare the effects of two treatments in medical science because it performs within-subject comparisons, which increase the precision of a treatment effect (i.e., a between-treatment differen
Publikováno v:
Statistics in Medicine. 32:5091-5105
Medical diagnostic tests must enjoy appropriate validity and high reliability in order to qualify as adequate assessment tools. Without a gold standard test, available medical diagnostic tests are not perfect; hence, the reliability of such tests mus